- Currently, he serves as chairman of the Yale School of Medicine’s Department of Cell Biology and director of the Nanobiology Institute on Yale’s West campus
- Rothman previously served as chief scientist of General Electric Healthcare
- Founded in 2013, Celesta has a portfolio of more than 100 early-stage technology investments
Celesta Capital, a deep tech venture capital firm, has named Dr. James Rothman as a senior advisor.
Celesta, which was founded in 2013 and has $1.1 billion in AUM, is currently fundraising for its fifth fund, which has not disclosed a target, according to a September regulatory filing.
Rothman was the recipient of the 2013 Nobel Prize in physiology or medicine. He currently serves as chairman of the Yale School of Medicine’s Department of Cell Biology and director of the Nanobiology Institute on Yale’s West campus.
“Jim is one of the most accomplished medical science researchers in the world and we’re delighted to welcome him to Celesta,” Celesta founding managing partner Michael Marks said in a statement. “His expertise will be invaluable to our growing portfolio of bio-convergence companies as they pursue such bold visions to advance healthcare.”
Rothman previously served as chief scientist of General Electric Healthcare. He has also advised leaders at Genentech, Merck & Co, GlaxoSmithKline and Eli Lilly. Prior to Yale, Rothman served as a professor at Stanford, Princeton, and Columbia universities. He founded and chaired the Department of Cellular Biochemistry and Biophysics at Memorial Sloan-Kettering Cancer Center.
Based in San Mateo, California, Celesta has a portfolio of more than 100 early-stage technology investments. The firm changed its name from WRVI Capital in 2021.
- Currently, he serves as chairman of the Yale School of Medicine’s Department of Cell Biology and director of the Nanobiology Institute on Yale’s West campus
- Rothman previously served as chief scientist of General Electric Healthcare
- Founded in 2013, Celesta has a portfolio of more than 100 early-stage technology investments
Celesta Capital, a deep tech venture capital firm, has named Dr. James Rothman as a senior advisor.
Celesta, which was founded in 2013 and has $1.1 billion in AUM, is currently fundraising for its fifth fund, which has not disclosed a target, according to a September regulatory filing.
Rothman was the recipient of the 2013 Nobel Prize in physiology or medicine. He currently serves as chairman of the Yale School of Medicine’s Department of Cell Biology and director of the Nanobiology Institute on Yale’s West campus.
“Jim is one of the most accomplished medical science researchers in the world and we’re delighted to welcome him to Celesta,” Celesta founding managing partner Michael Marks said in a statement. “His expertise will be invaluable to our growing portfolio of bio-convergence companies as they pursue such bold visions to advance healthcare.”
Rothman previously served as chief scientist of General Electric Healthcare. He has also advised leaders at Genentech, Merck & Co, GlaxoSmithKline and Eli Lilly. Prior to Yale, Rothman served as a professor at Stanford, Princeton, and Columbia universities. He founded and chaired the Department of Cellular Biochemistry and Biophysics at Memorial Sloan-Kettering Cancer Center.
Based in San Mateo, California, Celesta has a portfolio of more than 100 early-stage technology investments. The firm changed its name from WRVI Capital in 2021.
